Research emerging from the University of Toronto found that using machine learning models was able to guide the design of long-acting drug formulations.
Indegene’s partnership with Tealium leverages AI-driven data strategy for life sciences companies to navigate the industry’s connected technology ecosystem.
OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
The pharma company’s collaboration with the drug discovery specialist involves using artificial intelligence to discover and develop up to five drug targets.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
An expert from the trial tech company discusses tools that can prove useful for trial teams looking to avoid employee shortages plaguing other industries.
The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.
The institute will combine the university’s AI, ML, health science, engineering, genomics, and data capabilities to tackle health strategy and inequity.
The CRO has paired with the drug discovery technology firm on Logica, an artificial intelligence tool designed to accelerate development of new treatments.
An expert from the health tech company explains how AI, natural language processing, and other tools can improve pharmaceutical product safety reporting.
Experts from the Decentralized Trials and Research Alliance and Rafael Pharmaceuticals discuss progress and possibilities during Clinical Development Advances.
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
This month’s list of new technology, partnerships, and other announcements includes items from ObvioHealth, Datavant, HumanFirst, and other industry players.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
Alongside the first drug developed by AI entering clinical trials, there have been a number of other instances of the technology being used to aid the discovery of new treatments.
NVIDIA, King's College London, and Owkin team up to connect hospitals across the UK with federated learning, aiming to boost several fields of clinical research.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
Veeva Systems launches a software application aiming to reduce the time and effort of manual data entry, which will be integrated to its cloud-based suite.
'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.
Phesi launches an AI-powered SaaS solution to mitigate potential costly delays through a search and select investigator function to determine trial sites for clinical studies.
O2h Ventures and AI Fund invest in Small Pharma, as it works to complete studies for its lead program, a metabolite of ketamine as an oral anti-depressant.
Freenome is working with a CRO as part of a clinical trial evaluating the company’s multi-omics blood testing platform – which the CEO says helps de-risk drug development by characterizing likely responders to therapy, among other use cases.
Insilico Medicine develops a semi-automated contracting system to ease the collaboration process between AI companies and industry partners in the discovery space.
The Pistoia Alliance launches a project to steer the implementation of principles for data management and stewardship, which it said are required as the industry undertakes a digital transformation.
Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.
Navitas Life Sciences taps ThoughtSphere to power its digital and clinical analytics cloud-based clinical data SaaS OneClinical, as the company continues to grow after Kai Research acquisition.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Concerto HealthAI launches model to predict survival rates in lung cancer patients in an aim to garner disease insights that could improve enrollment criteria.
Artificial intelligence tools will allow the pharmaceutical companies to make predictions about diseases more effectively than before, says ImaginAB’s CEO.
The industrialized process the industry has developed over the years is not ready for the non-blockbuster environment its entering but AI can help, says Numerate executive.
